General
Preferred name
MOTESANIB
Synonyms
AMG-706 ()
AMG-706, Motesanib Diphosphate ()
AMG706 ()
AMG 706 ()
MOTESANIB DIPHOSPHATE ()
Motesanib (AMG706) ()
Motesanib (Diphosphate) ()
AMG 706 (Diphosphate) ()
Motesanib Diphosphate (AMG-706) ()
Motesanib (AMG-706) ()
MOTESANIB PHOSPHATE ()
P&D ID
PD012969
CAS
453562-69-1
857876-30-3
Tags
available
drug candidate
Drug indication
Non-small-cell lung cancer
Neoplasm
non-small cell lung carcinoma
Drug Status
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Motesanib is a pan-VEGFR inhibitor that was investigated for anti-tumourigenic efficacy.
(GtoPdb)
DESCRIPTION
Motesanib (AMG 706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.
PRICE
45
DESCRIPTION
Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.
PRICE
56
DESCRIPTION
Motesanib (AMG 706) is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
348
Organisms
0
Compound Sets
26
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
373.19
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
4.04
TPSA
78.94
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.63
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
VEGFR, RET, c-KIT, PDGFR
c-Kit
KIT
VEGFR
VEGFR1
VEGFR2
VEGFR2/Flk1
VEGFR3
FLT1, FLT4, KDR, KIT
VEGFR inhibitor
KDR
c-Kit,PDGFR,VEGFR
FLT1
FLT4
PDGFRA
PDGFRB
RET
Pathway
RTK signaling
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Targets
FLT1,KDR,FLT4
MOA
KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Recommended Cell Concentration
None
Source data
